

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

APOTEX, INC.  
Petitioner,

v.

UCB BIOPHARMA S.A.  
Patent Owner.

U.S. Patent No. 8,633,194 to Fanara *et al.*

Issue Date: January 21, 2014

Title: Pharmaceutical composition of piperazine derivatives

*Inter Partes* Review No.: IPR2019-00400

**Petitioner's Exhibit List**

**Petitioner's Exhibit List**

<b><i>Petitioner Exhibit #</i></b>	<b><i>Description</i></b>
<b>1001</b>	U.S. Patent No. 8,633,194 (“the ’194 patent”)
<b>1002</b>	Declaration of Dr. Laskar
<b>1003</b>	CV of Dr. Laskar
<b>1004</b>	European Patent Application Publication No. 0605203 A2 (“EP ’203”)
<b>1005</b>	Wang D.Y., “Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers,” <i>Allergy</i> 56 (2001), pp. 339-343 (“Wang”)
<b>1006</b>	Kibbe, “Handbook of Pharmaceutical Excipients,” 3rd ed. 2000 (the “Handbook”)
<b>1007</b>	International Patent Application No. WO 2004/050094 (“WO ’094”)
<b>1008</b>	Tillement, Jean-Paul <i>et al.</i> , “Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists,” <i>Biochemical Pharmacology</i> Volume 66, Issue 7, 1 October 2003, pages 1123-1126
<b>1009</b>	Potter, P.C., “Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites,” <i>Allergy</i> (Oxford, United Kingdom) Volume 58, Issue 9, pages 893-899, Journal 2003
<b>1010</b>	Gandon, J.M. <i>et al.</i> , “Lack of effect of single and repeated doses of Levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers,” <i>British Journal of Clinical Pharmacology</i> (2002), 54(1), 51-58
<b>1011</b>	Orange Book Entry for XYZAL
<b>1012</b>	R.J. Davies <i>et al.</i> , Antihistamines: topical vs. oral administration, <i>Clinical and Experimental Allergy</i> 26(3):11-17 (1996) (“Davies”)
<b>1013</b>	File Wrapper of ’194 patent
<b>1014</b>	Gennaro, A. R., Remington: The Science and Practice of Pharmacy 20th ed. (2000)
<b>1015</b>	U.S. Patent No. 5,698,558 to Nancy M. Grey (“US ’558”)
<b>1016</b>	EPO opposition
<b>1017</b>	Saeedi <i>et al.</i> , “The treatment of atopic dermatitis with licorice gel,” <i>Journal of Dermatological Treatment</i> (2003) 14, 1–5

<b>1018</b>	Duconge <i>et al.</i> , "Topical disposition of two strengths of a 125I-rhEGF jelly in rat skin wounds," <i>Biopharm. Drug Dispos.</i> 25: 193–201 (2004)
<b>1019</b>	U.S. Patent No. 4,275,076
<b>1020</b>	U.S. Patent No. 5,643,584
<b>1021</b>	Ansel <i>et al.</i> , <i>Pharmaceutical Dosage Forms and Drug Delivery Systems</i> 7th ed. 1999
<b>1022</b>	Soni <i>et al.</i> , "Evaluation of the health aspects of methyl paraben: a review of the published literature," <i>Food and Chemical Toxicology</i> 40 (2002) 1335–1373
<b>1023</b>	Sutton <i>et al.</i> , "Development of the Antimicrobial Effectiveness Test as USP Chapter <51>" <i>PDA Journal of Pharmaceutical Science and Technology</i> , Vol. 56, No. 6, 300-311, November/December 2002
<b>1024</b>	Darwish <i>et al.</i> , Effect of ethanol, propylene glycol and glycerol on the interaction of methyl and propyl <i>p</i> -hydroxybenzoate with <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> ," <i>Int. J. of Pharm.</i> 147:51-60 (1997).